Stereotaxis Inc (A:STXS)

Business Focus: Advanced Medical Equipment & Technology

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Company Contact
Address: 710 N Tucker Blvd, Ste 110
ST. LOUIS MO 63101
Tel: N/A
Website: https://www.stereotaxis.com
IR: See website
<
Key People
David Leo Fischel
Chairman of the Board, Chief Executive Officer
Kimberly R. Peery
Chief Financial Officer
 
Business Overview
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company's primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
Financial Overview
For the fiscal year ended 31 December 2023, Stereotaxis Inc revenues decreased 5% to $26.8M. Net loss applicable to common stockholders increased 12% to $22.1M. Revenues reflect United States segment decrease of 8% to $18.2M. Higher net loss reflects Manufactures and markets robotic magnetic navigation systems segment loss increase of 16% to $21.8M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.26 to -$0.27.
Employees: 122 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $191.90M as of Dec 31, 2023
Annual revenue (TTM): $26.77M as of Dec 31, 2023
EBITDA (TTM): -$21.24M as of Dec 31, 2023
Net annual income (TTM): -$22.06M as of Dec 31, 2023
Free cash flow (TTM): -$9.51M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 82,128,762 as of Feb 29, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.